Retsevmo (selpercatinib) vs Lumakras (sotorasib)

Retsevmo (selpercatinib) and Lumakras (sotorasib) are both targeted therapies for the treatment of certain types of cancer, but they target different genetic mutations. Retsevmo is specifically designed for cancers with RET gene alterations, such as non-small cell lung cancer (NSCLC), thyroid cancer, and other solid tumors, and has been shown to be effective in patients whose tumors have these alterations. On the other hand, Lumakras is the first FDA-approved therapy targeting the KRAS G12C mutation, which is present in a subset of NSCLC patients, and is indicated for those with this specific mutation after at least one prior systemic therapy. Patients should consult with their healthcare provider to determine the most appropriate treatment based on their individual cancer's genetic profile and previous treatments.

Difference between Retsevmo and Lumakras

Metric	Retsevmo (selpercatinib)	Lumakras (sotorasib)
Generic name	Selpercatinib	Sotorasib
Indications	Advanced RET-driven lung and thyroid cancers	Advanced non-small cell lung cancer with KRAS G12C mutation
Mechanism of action	RET kinase inhibitor	KRAS G12C inhibitor
Brand names	Retsevmo	Lumakras
Administrative route	Oral	Oral
Side effects	Increased liver enzymes, hypertension, dry mouth, diarrhea, fatigue, edema, rash, constipation	Diarrhea, musculoskeletal pain, nausea, fatigue, liver enzyme elevation, cough
Contraindications	Hypersensitivity to selpercatinib	Hypersensitivity to sotorasib
Drug class	Tyrosine kinase inhibitor	Small molecule kinase inhibitor
Manufacturer	Eli Lilly and Company	Amgen Inc.

Efficacy

Efficacy of Retsevmo (selpercatinib) in Lung Cancer

Retsevmo, known by its generic name selpercatinib, is a medication that has shown efficacy in the treatment of certain types of lung cancers. Specifically, it is approved for the treatment of non-small cell lung cancer (NSCLC) that is RET fusion-positive. RET fusion-positive NSCLC is a subset of lung cancer characterized by rearrangements in the RET gene. Clinical trials have demonstrated that selpercatinib has significant antitumor activity in patients with RET fusion-positive NSCLC, including those who have previously undergone treatment with platinum chemotherapy and those who are treatment-naive.

In the pivotal clinical trial, selpercatinib showed a high response rate in patients with RET fusion-positive NSCLC. The objective response rate (ORR) was observed to be around 64% in the overall population, with higher rates in treatment-naive patients. Additionally, the duration of response (DoR) was notably prolonged, with many patients experiencing sustained tumor shrinkage over time. These results indicate that selpercatinib is a potent targeted therapy for patients with RET fusion-positive NSCLC.

Efficacy of Lumakras (sotorasib) in Lung Cancer

Lumakras, also known as sotorasib, is a medication that targets a specific mutation in lung cancer known as the KRAS G12C mutation. This mutation is present in a subset of non-small cell lung cancers and has historically been considered 'undruggable'. However, Lumakras has emerged as the first approved targeted therapy for NSCLC patients with the KRAS G12C mutation. In clinical studies, sotorasib has demonstrated efficacy in shrinking tumors and slowing disease progression in patients with this specific genetic alteration.

The approval of Lumakras was based on the results of a phase 2 clinical trial that showed a notable ORR in patients with KRAS G12C-mutated NSCLC who had received at least one prior systemic therapy. The ORR was reported to be approximately 36%, with a median DoR of 10 months. While the response rate may seem modest compared to some other targeted therapies, it represents a significant advancement for patients with KRAS G12C-mutated NSCLC, for whom there were previously limited treatment options. The introduction of Lumakras has thus provided a new avenue of hope for patients with this challenging genetic profile of lung cancer.

Regulatory Agency Approvals

Retsevmo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Lumakras

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom

Access Retsevmo or Lumakras today

If Retsevmo or Lumakras are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Retsevmo

Buy Lumakras

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: